Cargando…

Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)

BACKGROUND: Patients with atrial fibrillation (AF) have a higher risk of fatal complications (e.g., stroke). This investigation was performed as an observational retrospective cohort study includes 137 patients (age 61 ± 15; 34.3% women) with a primary diagnosis of AF (paroxysmal, persistent, and pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gažová, Andrea, Leddy, John J., Rexová, Mária, Hlivák, Peter, Hatala, Róbert, Kyselovič, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708930/
https://www.ncbi.nlm.nih.gov/pubmed/31374021
http://dx.doi.org/10.1097/MD.0000000000016560
_version_ 1783446090503159808
author Gažová, Andrea
Leddy, John J.
Rexová, Mária
Hlivák, Peter
Hatala, Róbert
Kyselovič, Jan
author_facet Gažová, Andrea
Leddy, John J.
Rexová, Mária
Hlivák, Peter
Hatala, Róbert
Kyselovič, Jan
author_sort Gažová, Andrea
collection PubMed
description BACKGROUND: Patients with atrial fibrillation (AF) have a higher risk of fatal complications (e.g., stroke). This investigation was performed as an observational retrospective cohort study includes 137 patients (age 61 ± 15; 34.3% women) with a primary diagnosis of AF (paroxysmal, persistent, and permanent). METHODS: We collected information about the drug therapy, comorbidities and survival of AF patients and determined their congestive heart failure, hypertension, age, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age, sex category (CHA(2)DS(2)-VASc) scores. Statistical analysis identified patients with high CHA(2)DS(2)-VASc scores and defined the predictive value of individual parameters, or their combination, with regards to the outcomes of stroke and mortality. RESULTS: CHA(2)DS(2)-VASc scores identified 43.8% of the patients as low to intermediate risk (score 0–1) and 56.2% of the patients as high risk (score ≥2). Increasing CHA(2)DS(2)-VASc scores were not only accompanied by an increase in the incidence of stroke (P(trend) < .001) but also by an increase in the 3 to 5 years mortality (P = .005). Comparison of anticoagulation and anti-aggregation treatment between the 3 groups of AF did not show any significant statistical difference. Highly significant predictors of death were the CHA(2)DS(2)-VASc score (OR 1.71, 95% CI 1.10–2.67, P < .017) as well as other risk factors not included in the CHA(2)DS(2)-VASc score such as valvular heart disease (OR 5.04, 95% CI 1.10-23.10, P = .037), hyperlipidemia (OR 4.82, 95% CI 1.03–22.63, P = .046) and chronic renal failure (OR 14.21, 95% CI 2.41–83.91, P = .003). The type of AF type did not affect survival (P = .158) nor the incidence of stroke (P = .466). Patients with paroxysmal AF were linked to significantly lower frequencies of ischemic heart disease (P < .0001), vascular disease (P = .002), diabetes mellitus (P = .047), valvular heart disease (P = .03) and heart failure/left ventricular dysfunction (P = .015). CONCLUSION: The CHA(2)DS(2)-VASc score correctly predicted the patients at high-risk for 3 to 5 years mortality and confirmed its significant predictive value in the patients with AF.
format Online
Article
Text
id pubmed-6708930
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-67089302019-10-01 Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant) Gažová, Andrea Leddy, John J. Rexová, Mária Hlivák, Peter Hatala, Róbert Kyselovič, Jan Medicine (Baltimore) Research Article BACKGROUND: Patients with atrial fibrillation (AF) have a higher risk of fatal complications (e.g., stroke). This investigation was performed as an observational retrospective cohort study includes 137 patients (age 61 ± 15; 34.3% women) with a primary diagnosis of AF (paroxysmal, persistent, and permanent). METHODS: We collected information about the drug therapy, comorbidities and survival of AF patients and determined their congestive heart failure, hypertension, age, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age, sex category (CHA(2)DS(2)-VASc) scores. Statistical analysis identified patients with high CHA(2)DS(2)-VASc scores and defined the predictive value of individual parameters, or their combination, with regards to the outcomes of stroke and mortality. RESULTS: CHA(2)DS(2)-VASc scores identified 43.8% of the patients as low to intermediate risk (score 0–1) and 56.2% of the patients as high risk (score ≥2). Increasing CHA(2)DS(2)-VASc scores were not only accompanied by an increase in the incidence of stroke (P(trend) < .001) but also by an increase in the 3 to 5 years mortality (P = .005). Comparison of anticoagulation and anti-aggregation treatment between the 3 groups of AF did not show any significant statistical difference. Highly significant predictors of death were the CHA(2)DS(2)-VASc score (OR 1.71, 95% CI 1.10–2.67, P < .017) as well as other risk factors not included in the CHA(2)DS(2)-VASc score such as valvular heart disease (OR 5.04, 95% CI 1.10-23.10, P = .037), hyperlipidemia (OR 4.82, 95% CI 1.03–22.63, P = .046) and chronic renal failure (OR 14.21, 95% CI 2.41–83.91, P = .003). The type of AF type did not affect survival (P = .158) nor the incidence of stroke (P = .466). Patients with paroxysmal AF were linked to significantly lower frequencies of ischemic heart disease (P < .0001), vascular disease (P = .002), diabetes mellitus (P = .047), valvular heart disease (P = .03) and heart failure/left ventricular dysfunction (P = .015). CONCLUSION: The CHA(2)DS(2)-VASc score correctly predicted the patients at high-risk for 3 to 5 years mortality and confirmed its significant predictive value in the patients with AF. Wolters Kluwer Health 2019-08-02 /pmc/articles/PMC6708930/ /pubmed/31374021 http://dx.doi.org/10.1097/MD.0000000000016560 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Gažová, Andrea
Leddy, John J.
Rexová, Mária
Hlivák, Peter
Hatala, Róbert
Kyselovič, Jan
Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)
title Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)
title_full Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)
title_fullStr Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)
title_full_unstemmed Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)
title_short Predictive value of CHA(2)DS(2)-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant)
title_sort predictive value of cha(2)ds(2)-vasc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (consort compliant)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708930/
https://www.ncbi.nlm.nih.gov/pubmed/31374021
http://dx.doi.org/10.1097/MD.0000000000016560
work_keys_str_mv AT gazovaandrea predictivevalueofcha2ds2vascscoresregardingtheriskofstrokeandallcausemortalityinpatientswithatrialfibrillationconsortcompliant
AT leddyjohnj predictivevalueofcha2ds2vascscoresregardingtheriskofstrokeandallcausemortalityinpatientswithatrialfibrillationconsortcompliant
AT rexovamaria predictivevalueofcha2ds2vascscoresregardingtheriskofstrokeandallcausemortalityinpatientswithatrialfibrillationconsortcompliant
AT hlivakpeter predictivevalueofcha2ds2vascscoresregardingtheriskofstrokeandallcausemortalityinpatientswithatrialfibrillationconsortcompliant
AT hatalarobert predictivevalueofcha2ds2vascscoresregardingtheriskofstrokeandallcausemortalityinpatientswithatrialfibrillationconsortcompliant
AT kyselovicjan predictivevalueofcha2ds2vascscoresregardingtheriskofstrokeandallcausemortalityinpatientswithatrialfibrillationconsortcompliant